Skip to main content
Clinical Trials/DRKS00020989
DRKS00020989
Recruiting
N/A

A cognitive-behavioural approach for the treatment of fear of progression in patients wth Parkinson's disease and Multiple Sclerosis: A Mixed-Methods Study

Medizinische Psychologie | Neuropsychologie und Gender StudiesCentrum für Neuropsychologische Diagnostik und Intervention (CeNDI), Medizinische Fakultät und Uniklinik Köln, Universität zu Köln0 sites147 target enrollmentNovember 18, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Fear of Progression
Sponsor
Medizinische Psychologie | Neuropsychologie und Gender StudiesCentrum für Neuropsychologische Diagnostik und Intervention (CeNDI), Medizinische Fakultät und Uniklinik Köln, Universität zu Köln
Enrollment
147
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 18, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Medizinische Psychologie | Neuropsychologie und Gender StudiesCentrum für Neuropsychologische Diagnostik und Intervention (CeNDI), Medizinische Fakultät und Uniklinik Köln, Universität zu Köln

Eligibility Criteria

Inclusion Criteria

  • Inpatients of the neurological rehabilitation centre Godeshöhe e.V. Bonn;
  • Clinical PD or MS diagnosis;
  • Affirmation of item 1 and 3 of the psychosocial 3\-item requirement analysis:
  • 1\. Do you often suffer from the fear of the progression of your disease in everyday life?
  • 2\. If so, how strongly does the fear of progression affect your everyday life? (Numeric analogue scale from 0 to 10\)
  • 3\. Would you like to have support in dealing with this fear?;
  • The patients are able to follow instructions;
  • Unrestricted or sufficiently corrected sight and hearing;
  • German as mother tongue or sufficiently good knowledge of German

Exclusion Criteria

  • Severe cognitive impairment (Montreal Cognitive Assessment (MoCa) \= 12 points, cut\-off value between mild cognitive impairment and Alzheimer's dementia according to Nasreddine et al., 2005\) and therefore a limited or missing capacity for consent;
  • Presence of major depression (assessed by the General Depression Scale (ADS\-K), cut\-off value \= 17 according to Radloff, 1977\) and/or acute suicidal tendencies (assessed by the responsible psychologists of the Neurological Rehabilitation Centre Godeshöhe e.V. or information on patient record);
  • Severe neurological and psychiatric or life\-threatening comorbidities (e.g., acute episodes of affective disorders, personality disorders, psychoses or somatoform disorders; in each case assessed by the responsible psychologists of the Neurological Rehabilitation Centre Godeshöhe e.V. or information on patient records)

Outcomes

Primary Outcomes

Not specified

Similar Trials